Ac-225 Chloride (NCA)
For targeted alpha therapies
Ac-225 Chloride (NCA) is a highly effective radioisotope used in targeted alpha therapies – a new form of radionuclide therapy against various tumors for which there is a high medical need.
This transports alpha radiation directly to tumors in the body by combining alpha radionuclides such as actinium-225 with specific target molecules.
- carrier-free (NCA)
- does not contain Ac-227(!) as a decay product of Th-229
- in liquid form as chloride
Product Specifications
Ac-225 Chloride (NCA)
| Appearance | clear, colorless solution |
| Radionuclide identity | Alpha 225Ac for 5.830 keV, 5.793 keV, 5.791 keV |
| Quantity of radioactivity | ≥ 74 MBq/ml (≥ 2 mCi/ml) |
| chemical form | 225AcCl3 |
| Ratio of the total gamma radiation (with the exception of 225-Ac and its daughter isotopes) to 225-Ac activity | ≤ 1 |
| Ratio of alpha emitter activity to 225-Ac activity, inclusive, % - Radium-225 - radium-224 - other | ≤ 0,02 ≤ 0,002 ≤ 0,0007 |
| Content of non-radioactive impurities (Al, Cu, Fe, Ba, Mn, Zn, Ni, Mo, Cd, Be, Bi, Cr, Pb, Sn), μg/MBq (μg/mCi) | ≤ 0,27 (≤ 10) |
| Concentration of the solvent (HCl), mol/l | 0,1 |